A Retrospective, Cohort, Real World Study Analyzing Changes in Disease Activity and Patient-Reported Outcomes in Psoriatic Arthritis Patients Treated with Ixekizumab
Latest Information Update: 30 Dec 2022
Price :
$35 *
At a glance
- Drugs Ixekizumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- 14 Nov 2022 Results assessing changes in disease activity and patient-reported outcomes at 6 and 12 months follow-up among psoriatic arthritis patients initiating ixekizumab in a real-world setting, presented at the ACR Convergence 2022.
- 24 Jun 2022 New trial record
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism